Goldman Sachs Hikes Insmed (INSM) Price Target to $112 Affirms Buy Rating

Abdul Rahman

Tue, Jun 17, 2025, 1:24 AM 1 min read

Insmed Incorporated (NASDAQ:INSM) is one of the 12 best healthcare stocks to buy now. On June 11, Goldman Sachs analyst Andrea Tan reiterated a ‘Buy’ rating on the stock and increased the price target to $112 from $100. The adjustment underscores the analyst’s confidence about the company’s long-term prospects.

A scientist examining the glucocerebrosidase enzyme development with the aim of establishing therapeutics for Gaucher disease.

The Buy rating comes on the heels of the biopharmaceutical company raising $750 million in a public offering of common stock. It plans to use net proceeds from the offering to accelerate research and development efforts of brensocatib. Part of the funds will also finance the commercialization activities of ARIKAYCE. They will also support the development of treprostinil palmitil inhalation powder and other research initiatives.

Insmed Incorporated (NASDAQ:INSM) is a global biopharmaceutical company focused on developing and commercializing therapeutics for serious and rare diseases. It focuses on respiratory and rare diseases, specifically emphasizing metabolic diseases and endocrine disorders.

While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Stocks Analysts Are Upgrading Today and 13 Best AI Stocks to Buy Under $10.

Disclosure: None.